The process of streamlining Sangamos pipeline has been accelerated within todays challenging economic environment and we have had to make difficult decisions to defer further investments and seek collaboration partners or direct investment in both our Fabry gene therapy and CARTreg cell therapy programs said Sandy Macrae CEO of Sangamo in the companys statement